NASDAQ · Healthcare · Biotechnology
Relmada Therapeutics, Inc.
RLMD
Relmada Therapeutics, Inc. CEO Sergio Traversa · Market cap $340.9M.
$3.25
-0.03 · -0.91%
52w hi $8.0052w lo $1.80
Off 52w high 43.5%
75
STRONG
Current InsiderScore
Corp · 90d
4
4 buys · 0 sales
Cong · 90d
0
0 buys · 0 sales
Signals ≥ 60 · 12mo
8
2 strong · 6 notable
Analyst consensus
Strong Buy
Avg PT $12.00
Section 01
Recent Form 4 filings
19 filings on file
| Date | Insider | Role | Action | Shares | Price | Value | Score |
|---|---|---|---|---|---|---|---|
| Sep 10 | Maged Shenouda | Chief Financial Officer | Buy | 79,800 | $4.25 | +$339K | 69 |
| Sep 10 | Sergio Traversa | Chief Executive Officer | Buy | 100,000 | $4.10 | +$410K | 72 |
| Sep 09 | Sergio Traversa | Chief Executive Officer | Buy | 100,000 | $4.18 | +$418K | 72 |
| Sep 09 | Maged Shenouda | Chief Financial Officer | Buy | 120,200 | $4.20 | +$505K | 75 |
| Dec 15 | Maged Shenouda | Chief Financial Officer | Buy | 11,665 | $4.12 | +$48K | 47 |
| Dec 15 | Sergio Traversa | Chief Executive Officer | Buy | 27,500 | $4.12 | +$113K | 55 |
| Nov 05 | Maged Shenouda | Chief Financial Officer | Buy | 500,000 | $2.20 | +$1.10M | 76 |
| Nov 05 | Sergio Traversa | Chief Executive Officer | Buy | 272,500 | $2.20 | +$600K | 73 |
| Nov 05 | Chuck Ence | CAO and COO | Buy | 136,000 | $2.20 | +$299K | 70 |
| Nov 05 | Paul Edward Kelly | Chief Operating Officer | Buy | 90,000 | $2.20 | +$198K | 63 |
| Aug 28 | Sergio Traversa | Chief Executive Officer | Buy | 55,976 | $0.74 | +$41K | 43 |
| Aug 27 | Sergio Traversa | Chief Executive Officer | Buy | 129,455 | $0.67 | +$87K | 48 |
| Aug 26 | Sergio Traversa | Chief Executive Officer | Buy | 80,545 | $0.62 | +$50K | 46 |
| May 20 | Maged Shenouda | Chief Financial Officer | Buy | 60,000 | $0.52 | +$31K | 62 |
| May 20 | Sergio Traversa | Chief Executive Officer | Buy | 147,686 | $0.56 | +$82K | 67 |
| May 19 | Maged Shenouda | Chief Financial Officer | Buy | 90,000 | $0.49 | +$44K | 65 |
| May 16 | Paul Edward Kelly | Chief Operating Officer | Buy | 200,000 | $0.43 | +$86K | 67 |
| May 16 | Sergio Traversa | Chief Executive Officer | Buy | 172,314 | $0.45 | +$77K | 67 |
| May 16 | Chuck Ence | CA and CO | Buy | 228,961 | $0.45 | +$103K | 66 |
Section 02
Recent STOCK Act disclosures
No disclosures yet
No STOCK Act disclosures on record for this ticker.
Section 03
InsiderScore history
Rolling 12 months · peak score per month
NovDecJanFebMarAprMayJunJulAugSepOct